Protocols
11 protocol(s) meet the specified criteria
Drug: PLATINOL
Protocol No.TitleStatus
A091101Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) –a Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and NeckOpen
CALGB30610Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and EtoposideOpen (affiliates only)
CALGB90601-CIRBA Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell CarcinomaOpen (affiliates only)
LCCC1430Phase Ib trial of Dose-escalating AZD1775 in Combination with Concurrent Radiation and Cisplatin for Intermediate and High Risk Head and Neck Squamous Cell Carcinoma (HNSCC)Open
LCCC1520Phase 2 study of pembrolizumab in combination with gemcitabine and cisplatin as neoadjuvant therapy prior to radical cystectomy in patients with MIBCOpen
LCCC1612P53 mutational status and circulating free HPV DNA for the management of HPV-associated Oropharyngeal Squamous Cell Cancers Open
MSKCC-13-074Randomized phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) vs. bleomycin, etoposide and cisplatin (BEP) for patients with previously untreated intermediate- and poor- risk germ cell tumorsOpen
RTOG1008A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors Open
S1314-CIRBA Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder CancerOpen
S1416-CIRBPhase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast CancerOpen
TBCRC-030A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients with Triple Negative Breast Cancer Without Germline BRCA Mutations: Evaluating the Homologous Recombination Deficiency (HRD) BiomarkerOpen